ArticleInternational journal of molecular medicine2021
Upregulated miR‑411‑5p levels promote lymph node metastasis by targeting RYBP in head and neck squamous cell carcinoma.
Article in International journal of molecular medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 14 citations in OpenAlex.
- MiR-493-5p functions as a tumour suppressor in head and neck squamous cell carcinoma progression by targeting HIF-1α.Discover oncology · 2025Article
- Invasion and metastasis in cancer: molecular insights and therapeutic targets.Signal transduction and targeted therapy · 2025Review
- RYBP contributes to improved prognosis in colorectal cancer via regulation of cell cycle, apoptosis and oxaliplatin sensitivity.International journal of oncology · 2023Article
- Circulatory miR-411-5p as a Novel Prognostic Biomarker for Major Adverse Cardiovascular Events in Patients with Atrial Fibrillation.International journal of molecular sciences · 2023Article
- High-Metastatic Melanoma Cells Promote the Metastatic Capability of Low-Metastatic Melanoma CellsFrontiers in oncology · 2022Article
- MicroRNA-Mediated Regulation of the Virus Cycle and Pathogenesis in the SARS-CoV-2 Disease.International journal of molecular sciences · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metastasis is the primary cause of the high mortality rates in head and neck squamous cell carcinoma (HNSCC). MicroRNA (miR)‑411‑5p has been discovered to serve an important role in cancer metastases. However, to the best of our knowledge, the association between miR‑411‑5p expression levels and HNSCC metastasis has not been thoroughly investigated. The present study aimed to research the function of miR‑411‑5p in HNSCC metastasis. The results of the present study revealed that miR‑411‑5p expression levels were upregulated in patients with HNSCC with lymph node metastasis and the upregulated expression levels of miR‑411‑5p were positively associated with the metastatic potential of HNSCC. Moreover, miR‑411‑5p promoted HNSCC cell migration, invasion and epithelial‑mesenchymal transition (EMT). The results of the dual‑luciferase reporter assays identified RING1 and YY1 binding protein (RYBP) as a functional downstream target gene for miR‑411‑5p. Therefore, whether miR‑411‑5p downregulated the expression levels of RYBP in HNSCC cells was subsequently investigated. Notably, the silencing of RYBP expression restored the stimulatory effects of miR‑411‑5p on HNSCC cell migration, invasion and EMT. In addition, the mRNA expression levels of miR‑411‑5p and RYBP were found to be inversely correlated in HNSCC samples. In conclusion, the results of the present study indicated that the miR‑411‑5p‑mediated downregulation of RYBP expression levels may exert an important role in HNSCC metastasis and may provide a novel target for the treatment of HNSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.